GlassScriptPhysician profile
Suzanne B Merrill
NPI 1114194792
$102,200.24
in general payments reported to CMS, 2019-2025
25 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.33 · 2020: $11.18 · 2021: $108 · 2022: $2,154 · 2023: $10K · 2024: $48K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Honoraria: $19K · Travel and Lodging: $3,442 · Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,126.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,107.52 |
| Honoraria | $19,475.00 |
| Travel and Lodging | $3,441.91 |
| Food and Beverage | $2,734.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photocure INC | $32,362.14 | 2022-2025 | Cysview |
| Janssen Biotech, INC. | $27,176.29 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Urogen Pharma, INC. | $18,764.62 | 2022-2025 | |
| Astellas Pharma US INC | $4,883.32 | 2019-2025 | Padcev |
| Janssen Scientific Affairs, LLC | $4,824.56 | 2022-2025 | Erleada |
| Pfizer INC. | $4,685.73 | 2024-2025 | |
| Immunitybio, INC. | $4,322.81 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $2,827.76 | 2024-2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals LP | $1,611.00 | 2023 | |
| Abbvie INC. | $143.98 | 2023-2025 | Botox |
| Sumitomo Pharma America, INC. | $96.17 | 2023-2025 | Gemtesa, Orgovyx |
| Virtual Incision Corporation | $85.00 | 2024 | Mira |
| Tolmar, INC. | $78.50 | 2023 | |
| Coloplast Corp | $48.25 | 2021-2024 | |
| Axonics, INC. | $43.63 | 2022-2024 | Bulkamid, Axonics |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.55 | 2022 | |
| Merck Sharp & Dohme LLC | $33.81 | 2023-2025 | Welireg, Keytruda, Lynparza |
| Ambu INC. | $32.34 | 2023 | |
| Telix Pharmaceuticals | $29.27 | 2025 | Illuccix |
| Medtronic, INC. | $24.63 | 2025 | Signia |
| Biotissue Holdings INC. | $23.09 | 2025 | |
| Convatec INC. | $20.38 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.48 | 2023 | Opdivo |
| Dendreon Pharmaceuticals LLC | $15.75 | 2025 | Provenge |
| Ethicon US, LLC | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.